坦洛新联合前列安栓治疗Ⅲ型前列腺炎临床观察

目的 观察坦洛新联合前列安栓治疗Ⅲ型前列腺炎的临床疗效.方法 Ⅲ型前列腺炎患者90例,随机分为治疗组(n=45)和对照组(n=45),治疗组应用坦洛新和前列安栓,对照组应用特拉唑嗪和前列安栓,观察2组治疗前后的慢性前列腺炎症状积分指数(NIH-CPSI评分)和疗效变化,并进行统计学分析.结果 治疗组:临床痊愈12例,显效14例,有效16例,无效3例,总有效率93.3%;对照组:临床痊愈5例,显效9例,有效17例,无效12例,总有效率72.1%.治疗组优于对照组(P<0.05):治疗组在改善患者尿路症状、生活质量及总NIH-CPSI方面优于对照组(P<0.05);两者在改善疼痛症状上无明显差异(P>0.1).结论 坦洛新联用前列安栓是治疗Ⅲ型前列腺炎有效的药物组合.     

前列安栓治疗慢性前列腺炎综合征的疗效观察

目的 评估前列安栓在治疗慢性前列腺炎综合征中的临床疗效。方法 采用随机开放前瞻对照试验方法,将120例慢性前列腺炎患者随机分为两组:前列安栓治疗组(A组)和常规治疗对照组(B组),分别采用前列安栓联用氧氟沙星或单用氧氟沙星治疗。以前列腺按摩液(EPS)检查和NIH前列腺炎症状评分作为评估手段,对每个患者随访4周观察临床疗效。结果 本研究中共有6例患者未能完成第2周的随访而退出试验,其中A组2例在第1周末因腹痛、腹泻拒绝进一步治疗,B组2例失访,2例因对疗效不满意而退出,其余病例均完成了4周的随访。结果显示:前列安栓治疗组临床痊愈10例(17.2％),显效20例(34.5％),有效19例(32.6％),总显效率51.7％,总有效率83.3％,明显优于对照组(总显效率和总有效率分别为31.7％和66.7％),P<0.01。结论 前列安栓直肠给药联合口服抗生素对慢性前列腺炎综合征具有较好的疗效。前列安栓直肠给药是治疗慢性前列腺炎的新选择。     

前列安栓治疗慢性前列腺炎350例临床分析

目的:评估前列安栓治疗慢性前列腺炎的临床效果.方法:将350例慢性前列腺炎患者随机分成前列安栓组和抗生素对照组,前列安栓组每日一粒前列安栓于晚间便后塞入肛门3～5 cm ;抗生素组单用广谱抗生素或抗革兰阴性菌的药物.对两组疗效进行分析评估.结果:前列安栓组总有效率达81%,抗生素对照组有效率40%,差异有统计学意义.结论:前列安栓治疗慢性前列腺炎临床效果满意,是治疗慢性前列腺炎有效药物之一,值得在基层医疗机构推广.     

前列安栓治疗慢性前列腺炎的疗效和安全性

目的 :评估前列安栓治疗慢性前列腺炎的有效性和安全性。　方法 :本试验为随机分组 ,单盲对照 ,持续 4周的临床研究。共有 4 10例受试者参与本研究。　结果 :对观察指标的分析结果显示 ,前列安栓治疗慢性前列腺炎的临床痊愈 4 7例 ( 15 .2 % ) ,显效 118例 ( 3 8.1% ) ,有效 10 4例 ( 3 3 .5 % ) ,总显效率 5 3 .3 % ,总有效率 86.8% ,明显优于对照组的 2 9.0 %和 66.0 %。治疗组中 3 9例用药后有肛门不适、排便感 ,5例有腹痛、腹泻症状 ,经改进使用方法 ,即将前列安栓置入更深一些 ,病人症状减轻或消失 ,均未有停药。　结论 :前列安栓治疗慢性前列腺炎的疗效肯定 ,明显改善临床症状 ,可作为治疗慢性前列腺炎的一种新药推广应用     

前列安栓治疗慢性前列腺炎:多中心双盲随机安慰剂对照试验

目的　评估前列安栓治疗慢性前列腺炎各种疼痛和不适感等症状的有效性、安全性和依从性。　方法　安慰剂对照随机双盲试验。 72例慢性前列腺炎患者随机分为两组。治疗组 36例 ,每晚前列安栓 1粒纳肛 ,连续 1个月 ;对照组 36例 ,安慰剂治疗 1个月。根据前列腺按摩液 (EPS)和美国国立卫生院 (NIH)前列腺炎症状评分评估疗效。　结果　治疗组痊愈 1例 (2 .8% ) ,显效 7例(2 0 .0 % ) ,有效 16例 (45 .7% ) ,总显效率 2 2 .8% ,总有效率 6 8.6 %。对照组无痊愈病例 ,显效 2例(5 .7% ) ,有效 8例 (2 2 .8% ) ,总显效率 5 .7% ,总有效率 2 8.6 %。两组各有 1例在治疗 2周内退出试验。两组相比 ,总有效率和总显效率差别均有显著性意义 (P <0 .0 5 ) ;不良反应发生率差别无显著性意义 (P >0 .0 5 )。　结论　前列安栓治疗慢性前列腺炎安全、有效 ,患者依从性较好     

前列安栓治疗慢性前列腺炎综合征29例疗效观察

目的 :评估前列安栓治疗慢性前列腺炎 (CP)综合征各种疼痛和不适感等症状的有效性、安全性和治疗依从性。　方法 :采用持续 1个月的病例开放自身对照研究方法。根据美国国立卫生研究院 (NIH)前列腺炎症状评分表 ,对 2 9例前列腺按摩液 (EPS)进行检查 ,WBC≥ 10个 /HP、临床诊断为CP综合征的病人应用前列安栓进行治疗。并对每个病人接受前列安栓治疗前后的疗效进行观察。　结果 :本组病例治疗后与治疗前相比 ,其NIH前列腺炎症状评分、前列腺液的白细胞计数等均明显降低 ,其中显效 18例 ( 62 .1% ) ,有效 8例 ( 2 7.6% ) ,无效 3例( 10 .3 % )。　结论 :前列安栓治疗CP综合征安全、有效、使用方便 ,病人的依从性较好。     

酒石酸托特罗定片联合前列安栓防治前列腺电切术后膀胱痉挛20例

目的:评价酒石酸托特罗定片与前列安栓联合应用对前列腺电切术后膀胱痉挛的治疗效果。方法:随机将40例前列腺增生电切术后患者分成观察组和对照组各20例,观察组手术当日酒石酸托特罗定口服片剂;前列安栓塞入直肠。对照组膀胱痉挛症状出现后曲马多100mg肌肉注射。结果:观察组在术后第2、3d膀胱痉挛次数、平均持续时间均少于对照组。结论:酒石酸托特罗定片联合前列安栓对前列腺电切术后膀胱痉挛有较好的治疗效果。     

前列安栓治疗慢性前列腺炎(湿热瘀血壅阻证)的安全性和有效性的Ⅲ期临床试验

目的:评价前列安栓治疗慢性前列腺炎(湿热瘀血壅阻证)的安全性和有效性。方法:随机、单盲、平行对照、多中心临床试验,467例受试者分为试验组349例、对照组118例。试验组前列安栓1粒,对照组野菊花栓1粒,肛内用药每晚1次,疗程28 d。以中医证候、美国国立卫生研究院慢性前列腺炎症状评分(NIH-CPSI)、主要临床症状及前列腺按摩液白细胞(EPS-WBC)计数为疗效评价指标。结果:试验组治疗结束时中医证候疗效临床控制率为4.4%、总显效率为58.0%、总有效率为90.7%,明显优于对照组的0.9%、33.1%、70.4%(P<0.025)。试验组的NIH-CPSI总分、疼痛与不适、排尿情况、生存质量评分的下降程度均较对照组明显(P<0.025)。试验组对主要临床症状尿急、会阴部等局部坠胀和局部疼痛有明显缓解作用,疗效优于对照组(P<0.05)。试验组EPS-WBC计数改善率为55.2%,明显优于对照组的32.4%(P<0.05)。试验组和对照组均未发生严重不良事件,试验药和对照药不良反应发生率低,分别为0.56%(2/349)和0.83%(1/118)。结论:前列安栓治疗慢性前列腺炎(湿热瘀血壅阻证)疗效肯定,临床用药安全性良好。     

太宁栓应用于白领患者吻合器痔上黏膜环切术术后的疗效及临床分析

目的:探讨太宁栓应用于白领患者吻合器痔上黏膜环切术(pph)术后的疗效及临床分析.方法:将120例白领痔疮患者分为观察组(太宁栓塞肛)和对照组(马应龙麝香痔疮膏涂抹),每组各60例,治疗14天后,对两组白领痔疮患者术后疼痛的临床疗效、创面愈合情况进行观察,并进行比较.结果:60例观察组中,42例显效,1 5例有效,3例无效;60例对照组中,18例显效,21例有效,21例无效.与对照组的总有效率(65％)相比,观察组的总有效率明显升高(9 5％),P＜0.05.与对照组的完全愈合率(77％)相比,观察组的完全愈合率明显升高(95％),P＜0.05.结论:太宁栓应用于白领患者,具有较好的止痛效果,明显促进创面愈合.     

川参通直接注入前列腺治疗慢性非细菌性前列腺炎/慢性盆腔疼痛综合征

目的:观察川参通直接注入前列腺治疗慢性非细菌性前列腺炎/慢性盆腔疼痛综合征(CABP/CPPS)的疗效与安全性。方法:用川参通及利多卡因注射液5 m l,经会阴注射至前列腺,每日1次,共6次,治疗98例CABP/CPPS患者。采用美国国立卫生研究院(NIH)制定的前列腺炎症状评分(CPSI)标准判定疗效。结果:观察12周,治愈53例(54.08%),显效17例(17.35%),有效23例(23.47%),总显效率71.43%,总有效率94.90%。川参通治疗前后,CPSI疼痛评分、排尿症状评分、生活质量评分及总分均有显著改善(95%可信区间分别为:6.83~9.41,2.16~3.94,2.95~5.43,12.85~17.91)。结论:经会阴前列腺内注射川参通治疗CABP/CPPS有效、安全。     

氯美扎酮联合α1受体阻滞剂治疗慢性非细菌性前列腺炎／慢性骨盆疼痛综合征的疗效观察

目的：评价氯美扎酮联合α1受体阻滞剂治疗慢性非细菌性前列腺炎，慢性骨盆疼痛综合征（CPPS-ⅢB）的疗效。方法：对符合CPPS-ⅢB诊断标准的62例患者随机分为治疗组及对照组．治疗组口服氯关扎酮（0．2g，每天3次，饭后服）及特拉唑嗪（2mg，每天1次，晚服），对照组仅口服特拉唑嗪（2mg，每天1次．晚服），疗程8周。评价指标包括症状评分、生活质量评分及最大尿流率等。结果：62例患暂均获随访，治疗组有效30例（93．8％），其中临床治愈9例（28．1％），无效2例（6．3％）；对照组有效24例（80％）．其中临床治愈4例（13．3％），无效6例（20％），两组相比差异有统计学意义（P〈0．05）。治疗过程中无严重不良反喧发牛。结论：氯美扎酮联合α1受体阻滞剂可作为CPPS-ⅢB的一种有效治疗手段。     

前列腺内直接注射川参通治疗慢性非细菌性前列腺炎/慢性骨盆疼痛综合征

目的 :评价经会阴注射川参通治疗慢性非细菌性前列腺炎 /慢性骨盆疼痛综合征 (CAP/CPPS)的有效性和安全性。　方法 :安慰剂对照双盲试验 ,将 38例诊断为CAP/CPPS的患者随机分为 2组。治疗组 2 4例 ,运用川参通及利多卡因注射液 6ml,经会阴注射至前列腺 ,每日 1次 ,共 6次 ;对照组 14例 ,安慰剂治疗 6次。采用美国国立卫生研究院 (NIH)制定的前列腺炎症状评分 (CPSI)标准判定疗效 ,比较治疗组治疗前后精液的主要参数。　结果 :观察 6周 ,两组各有 1例在治疗中退出试验。治疗组痊愈 13例 ( 5 6 .5 % ) ,显效 5例 ( 2 1.7% ) ,有效 4例 ( 17.4 % )。对照组无痊愈病例 ( 0 % ) ,显效 2例 ( 15 .4 % ) ,有效 3例 ( 2 3% )。治疗组痊愈率、显效率及有效率显著高于对照组 (P <0 .0 5 )。川参通治疗前后 ,CPSI疼痛评分、排尿症状评分、生活质量评分及总分均有显著改善 ( 95 %可信区间分别为 :9.83至 12 .70 ,3.15至 4 .94 ,3.95至 6 .4 8,17.97至 2 3.0 8)。对精液主要参数无显著性影响 (P >0 .0 5 )。　结论 :经会阴注射川参通治疗CAP/CPPS有效、安全。     

Cryotherapy alleviates symptoms in chronic prostatitis/chronic pelvic pain syndrome: The first results

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is an intractable disease. This study aimed to assess the efficacy of cryotherapy in the therapy of CP/CPPS. One hundred and seventy-two patients with CP/CPPS were randomised to receive cryotherapy or sham cryotherapy. The follow-up assessments were done at weeks 4, 12 and 24 using Visual Analogue Scale (VAS), International Prostate Symptom Score (IPSS) and National Institutes of Health-developed Chronic Prostatitis Symptom Index. The per-protocol analysis was performed. Eighty-two patients in the cryotherapy group and 76 patients in the sham group completed the treatment. The most obvious improvement (67%) of the VAS was observed in the cryotherapy group after 4 weeks, and although the improvement slightly weakened by 24 weeks (62.6%), a significant improvement from the treatment remained apparent. IPSS improved by 75% after 4 weeks and remained stable after 24 weeks. The response rates were 78.0%, 73.2% and 70.1% at weeks 4, 12 and 24 in the cryotherapy group, which were higher than 17.1%, 13.2% and 10.5% in the sham group (each p < .001). These results indicated that cryotherapy could alleviate voiding symptoms, ameliorate pain and improve the quality of life in people with CP/CPPS. It holds promise as a novel strategy to treat CP/CPPS.     

高频热疗联合吲哚美辛治疗慢性非细菌性前列腺炎/骨盆疼痛综合征的研究

目的:评价高频热疗联合吲哚美辛治疗慢性非细菌性前列腺炎/骨盆疼痛综合征(CPPS)的方法和疗效。方法:采用高频热疗联合吲哚美辛治疗CPPS患者321例,并观察其治疗效果。结果:治疗1个月后,临床治愈163例,占50.78%;显效112例,占34.89%;有效27例,占8.41%;无效19例,占5.91%。结论:高频热疗联合吲哚美辛是一种治疗CPPS患者安全、有效的方法     

慢性前列腺炎/慢性盆腔疼痛综合征与勃起功能障碍的临床预测

目的应用临床指标,预测慢性前列腺炎/慢性盆腔疼痛综合征（CP/CPSS）发生勃起功能障碍（ED）的可能性。方法以90例门诊确诊的慢性前列腺炎/慢性盆腔疼痛综合征患者为研究对象,分为发生ED组（A组）23例,未发生ED组（B组）67例,分别比较两组间在硫酸脱氢表雄酮（DHEAS）、24h尿香草扁桃体酸（VMA）、年龄等观察指标上的差异性,寻找其中能用于预测ED的临床指标。结果A组平均DHEAS值低于B组,VMA值高于B组,年龄方面两组差异无统计学意义。结论可通过DHEAS、VMA来预测慢性前列腺炎/慢性盆腔疼痛综合征患者ED的发生,有利于对慢性前列腺炎/慢性盆腔疼痛综合征发生ED患者的监控和治疗干预。     

生物反馈和电刺激联合治疗慢性前列腺炎/慢性骨盆疼痛综合征

目的:通过临床试验的方法,探讨生物反馈和电刺激联合治疗慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS)的效果。方法:收集湘雅医院门诊诊断为CP/CPPS符合研究标准患者140例。将患者随机分为对照组、生物反馈组、电刺激组和生物反馈加电刺激组;对照组20例,生物反馈组、电刺激组和生物反馈加电刺激组各40例。采用Laborie-Urostym生物反馈电刺激治疗仪,生物反馈组行生物反馈治疗,电刺激组行电刺激治疗,生物反馈加电刺激组行生物反馈电刺激治疗;每周5次,连续2周;对照组不予上述治疗,随诊1个月。治疗前后进行NIH-CPSI评分以及尿流率检查。结果:生物反馈组、电刺激组和生物反馈加电刺激组治疗后NIH-CPSI疼痛与不适评分、NIH-CPSI排尿症状评分、NIH-CPSI生活质量评分、NIH-CPSI总评分、最大尿流率较治疗前均有显著改善(P<0.05);治疗前各组积分及最大尿流率比较无显著差异(P>0.05);治疗后上述参数生物反馈组、电刺激组比较没有显著差异(P>0.05),生物反馈加电刺激组与生物反馈组、电刺激组比较有显著差异(P<0.05)。而对照组治疗前后的以上各组评分及最大尿流率比较无显著差异(P>0.05)。结论:生物反馈和电刺激治疗能明显改善CP/CPPS患者疼痛与不适症状,排尿症状,提高生活质量,以及提高最大尿流率。生物反馈和电刺激联合治疗CP/CPPS有协同作用。     

Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men

PURPOSE: A perspective on the neurobehavioral component of the etiology of chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS) is emerging. We evaluated a new approach to the treatment of CP/CPPS with the Stanford developed protocol using myofascial trigger point assessment and release therapy (MFRT) in conjunction with paradoxical relaxation therapy (PRT). MATERIALS AND METHODS: A total of 138 men with CP/CPPS refractory to traditional therapy were treated for at least 1 month with the MFRT/PRT protocol by a team comprising a urologist, physiotherapist and psychologist. Symptoms were assessed with a pelvic pain symptom survey (PPSS) and National Institutes of Health-CP Symptom Index. Patient reported perceptions of overall effects of therapy were documented on a global response assessment questionnaire. RESULTS: Global response assessments of moderately improved or markedly improved, considered clinical successes, were reported by 72% of patients. More than half of patients treated with the MFRT/PRT protocol had a 25% or greater decrease in pain and urinary symptom scores, as assessed by the PPSS. In those at the 50% or greater improvement level median scores decreased 69% and 80% for pain and urinary symptoms, respectively. The 2 scores decreased significantly by a median of 8 points when the 25% or greater improvement was first observed, that is after a median of 5 therapy sessions. PPSS and National Institutes of Health-CP Symptom Index showed similar levels of improvement after MFRT/PRT protocol therapy. CONCLUSIONS: This case study analysis indicates that MFRT combined with PRT represents an effective therapeutic approach for the management of CP/CPPS, providing pain and urinary symptom relief superior to that of traditional therapy.     

Pelvic floor electromyography in men with chronic pelvic pain syndrome: a case-control study

AIMS: The objectives of this study were (1) to identify differences between men with chronic pelvic pain syndrome (CPPS), compared with pain-free men, in surface electromyography/biofeedback (sEMG/BFB) readings of pelvic floor muscles and (2) to determine which pelvic floor muscle sEMG readings may have differential diagnostic and treatment selection value by accurately predicting group membership, CPPS versus normal. METHODS: Twenty-one men with CPPS and 21 healthy men without pelvic pain underwent a standardized sEMG examination by a licensed physical therapist. RESULTS: On group difference measures men with CPPS showed significantly greater sEMG instability in preliminary resting baseline. Three sEMG measures reliably categorized CPPS versus normals with CPPS showing greater preliminary resting baseline hypertonicity and instability with lowered voluntary endurance contraction amplitude. CONCLUSIONS: CPPS patients manifest pelvic floor muscle instability compared to normals. Prebaseline resting hypertonicity and instability along with endurance contraction weakness reliably predicts subject membership in the CPPS vs. normal group. Pelvic floor muscle sEMG may be a valuable screening tool to identify patients with CPPS who may benefit from therapies aimed at correcting pelvic floor muscle dysfunction.     

Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study

Purpose:We evaluated the efficacy and tolerability of pentosan polysulfate sodium (PPS) for the treatment of men with chronic pelvic pain syndrome (CPPS), National Institutes of Health (NIH) category III.Materials and Methods:In a 16-week double-blind study 100 men with a clinical diagnosis of CPPS were randomized to receive 300 mg PPS or placebo 3 times daily. Clinical Global Improvement (CGI) was the primary outcome measure. Additional outcome measures were the NIH-Chronic Prostatitis Symptom Index (CPSI), Subjective Global Assessment and Symptom Severity Index assessment tools.Results:Significantly more patients receiving PPS experienced moderate to marked improvement based on CGI assessment (18 or 37% vs 8 or 18%, p = 0.04). However, mean CGI scores were not significantly different between the PPS group (1.0) and placebo groups (1.0 vs 0.6, p = 0.107). All NIH-CPSI domains suggested a positive effect for PPS and for total NIH-CPSI the difference approached statistical significance (−5.9 or 22% vs −3.2 or 12%, p = 0.068). The PPS group showed significantly greater improvement in NIH-CPSI quality of life domain scores than the placebo group (−2.0 or 22% vs −1.0 or 12%, p = 0.031). Of patients receiving PPS 67% and 80% of those receiving placebo completed the 16-week study. Diarrhea, nausea and headache were the most common adverse events.Conclusions:Pentosan polysulfate (900 mg daily) was more likely than placebo to provide relief for CPPS symptoms.